Aduro BioTech (NASDAQ:ADRO) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.05), Fidelity Earnings reports. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.56 million. Aduro BioTech had a negative return on equity of 63.81% and a negative net margin of 784.73%.
Shares of ADRO traded down $0.05 during trading on Friday, reaching $1.35. The company’s stock had a trading volume of 341,152 shares, compared to its average volume of 389,110. The business’s fifty day moving average price is $1.57. Aduro BioTech has a twelve month low of $1.25 and a twelve month high of $8.10. The company has a market cap of $108.05 million, a P/E ratio of -1.16 and a beta of 1.48. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.11 and a current ratio of 9.11.
Several research firms recently commented on ADRO. Oppenheimer lowered Aduro BioTech from an “outperform” rating to a “market perform” rating in a research report on Monday, June 3rd. Cowen reissued a “buy” rating on shares of Aduro BioTech in a research report on Friday. Zacks Investment Research lowered Aduro BioTech from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Leerink Swann initiated coverage on Aduro BioTech in a research report on Monday, April 15th. They issued an “outperform” rating on the stock. Finally, Svb Leerink reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Aduro BioTech in a research report on Monday, April 15th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $8.01.
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.